Metabolife 356 “Unreasonably Dangerous,” Jury Says In $4.1 Mil. Verdict
This article was originally published in The Tan Sheet
Executive Summary
Metabolife sold its ephedrine alkaloid-containing Metabolife 356 in a "defective condition unreasonably dangerous to an ultimate user," a Birmingham, Ala. federal jury concluded in four cases Nov. 19